Compare Inovio Pharmaceuticals Inc (INO) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Workiva Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while Workiva Inc trades at $67.92 (market cap $3.76B). The key difference: Workiva Inc is far larger — about 47.9× Inovio Pharmaceuticals Inc's market cap, and Workiva Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | WK | |
|---|---|---|
Market Cap | $78.55M | $3.76B |
Sector | Health | Technology |
52-Week High | $2.87 | $93.31 |
52-Week Low | $0.66 | $44.31 |
Enterprise Value | $49.56M | $3.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Workiva (WK) trades at $67.62, up 0.45% with strong technical momentum and bullish analyst sentiment. The stock shows robust earnings performance with three consecutive quarterly beats and revenue growth accelerating to 19% in Q2 2026. Technical indicators signal bullish momentum despite overbought RSI conditions, while fundamentals reflect improving profitability with net income margin turning positive to 4.87% in 2026.
Outlook remains positive with 89% analyst buy ratings and $69 consensus target offering 2% upside. Key opportunities include AI product expansion and sustained subscription growth, while risks involve high valuation multiples (P/E 82.2) and competitive pressures in regulatory software. The stock's proximity to 52-week highs suggests momentum but warrants caution on pullbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
